Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Chief Scientific Officer | September 06, 2022 | September 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tyra Biosciences, Inc.
Report date September 06, 2022 · Filed September 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 273,254 |
Reported balance
After 2022-03-15 transaction · row 1
1 source rowRow 1 · 2022-03-15 · Grant · Acquired 3,125 · Balance 273,254 F1: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.14 · Expires 2032-09-05 | Direct | 105,000 |
Reported balance
After 2022-09-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-09-06 · Grant · Acquired 105,000 · Balance 105,000 F2: 1/48th of the shares subject to the option vest monthly following September 6, 2022, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.
F2: 1/48th of the shares subject to the option vest monthly following September 6, 2022, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 06, 2022 Filed Sep 8, 2022 21:51 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001209191-22-049217 · doc4.xml · derivative · entry 2 Swanson Ronald V. · CIK 0001880662 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2032-09-05 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following September 6, 2022, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| March 15, 2022 Filed Sep 8, 2022 21:51 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock | 3,125 | $8.53 | $26,642.19 |
DisclosureSEC source: 0001209191-22-049217 · doc4.xml · nonDerivative · entry 1 Swanson Ronald V. · CIK 0001880662 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,254 F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 7,964 | $0.00 Strike: $24.15 | $0.00 |
DisclosureSEC source: 0001209191-21-063014 · doc4.xml · derivative · entry 3 Swanson Ronald V. · CIK 0001880662 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,964 Underlying: Common Stock · 7,964 shares Expires 2031-11-01 F2 · derivative.exercise_date: The option vests based on achievement of a performance objective. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 7,964 | $0.00 Strike: $24.15 | $0.00 |
DisclosureSEC source: 0001209191-21-063014 · doc4.xml · derivative · entry 2 Swanson Ronald V. · CIK 0001880662 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,964 Underlying: Common Stock · 7,964 shares Expires 2031-11-01 F2 · derivative.exercise_date: The option vests based on achievement of a performance objective. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 83,626 | $0.00 Strike: $24.15 | $0.00 |
DisclosureSEC source: 0001209191-21-063014 · doc4.xml · derivative · entry 1 Swanson Ronald V. · CIK 0001880662 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,626 Underlying: Common Stock · 83,626 shares Expires 2031-11-01 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following November 2, 2021, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.